01 / 05
The Myth of the “Autism Epidemic”

Blog Post | Health & Demographics

The Myth of the “Autism Epidemic”

Most new cases reflect mild or no significant impairment. Moderate and severe cases have declined.

Summary: The perceived “autism epidemic” is largely driven by broadened diagnostic criteria and increased identification of mild, non-impairing cases rather than a true increase in severe autism. Cultural and institutional factors—like overdiagnosis and shifting norms in child psychiatry—play a significant role. Public health efforts are being misdirected by alarmist narratives and should instead focus on genuine health crises and more consistent, clinically meaningful diagnostic standards.


For years, public health debate has often fixated on a supposed rise in the prevalence of autism. Various culprits have been named, including the well-investigated but unsubstantiated claim that vaccines cause autism. More recently, additional risk factors have been proposed — many by Health Secretary Robert F. Kennedy Jr. — including maternal Tylenol use, food dyes and additives, chemical manufacturing agents and other possible stressors affecting perinatal development. Concerns about autism have been spotlighted within the larger Make America Healthy Again movement, motivated by a well-founded alarm over the nation’s devastatingly high burden of chronic disease and psychiatric illness. But there is a bigger problem with the autism epidemic: It doesn’t exist.

Autism diagnoses have indeed risen dramatically in recent decades. The most recently released Centers for Disease Control and Prevention report on autism, which was published in April last year, revealed a nearly five-fold increase in the prevalence of autism between 2000 and 2022, from 67 to 322 cases per 10,000 children. However, diagnostic criteria can change even when the underlying health phenomenon remains unchanged. A large-scale study published in December, drawing on CDC data from 24,669 8-year-olds across the country, suggests that the dramatic rise in autism diagnoses may be entirely driven by children with mild symptoms and no significant functional impairment. Between 2000 and 2016, there was a 464 percent increase in diagnoses among children with no significant functional impairment whatsoever. In fact, during the same time period, there was a 20 percent decrease in the prevalence of moderate or severe autism, from 15 to 12 cases per 10,000 children.

There is often a lag of several years before such epidemiological datasets are released, and years more for researchers to perform statistical analyses, publish the findings and enter public policy discussions. We do not yet have data more recent than 2016 breaking down symptoms by severity level while controlling for other psychological factors such as intellectual disability. However, given the trends observed between 2000 and 2016, it is highly unlikely that the additional 74 percent increase in autism diagnoses between 2016 and 2022 reflects a sudden surge in severe, functionally impairing autism. Rather, it is more likely a continuation of the same problem of overrepresentation among children with mild symptoms and no significant functional impairment.

Despite that, some advocates support the narrative that autism is on the rise, because an ever-expanding “spectrum” that produces more diagnoses draws more attention and research funding — even if children’s underlying psychology remains unchanged.

Some of the CDC’s data documenting the supposed rise in the characteristics of autism, meanwhile, comes not from gold-standard in-person psychiatric assessments but from parent-reported surveys such as the Social Responsiveness Scale. The SRS includes statements such as “Would rather be alone than with others,” “Has difficulty making friends,” and “Is regarded by other children as odd or weird,” which parents rate from “Not true” to “Almost always true.” In my own doctoral research on adolescent mental health, I included the SRS to account for the extent to which other psychological outcomes were explained by social difficulties. However, I was always careful to use hedging language — these are behavioral traits known to be associated with autism, not diagnostic markers. Unfortunately, many studies use high scores on the SRS as a substitute for clinical assessment of autism — accounting, for example, for at least 12 percent of “suspected cases” in the 2022 CDC data.

We should be concerned about the rising number of quirky children “on the spectrum,” but not because they are being exposed to neurotoxins that older generations were insulated from, nor because a growing number of children face clinicallysignificant social impairment. Rather, as Abigail Shrier argues in her 2024 book “Bad Therapy,” the more pressing concern may be a cultural and institutional drift toward overdiagnosis across child psychiatry. Like the rise in attention-deficit/hyperactivity disorder, anxiety and depression diagnoses among young people, the surge in autism labels may reflect shifting norms, looser diagnostic criteria and excess therapeutic attention directed toward ordinary struggles. If autism were truly increasing because of a new environmental insult, we would expect to see increases across all levels of severity. But that is not the case.

This reality should fundamentally reshape our national conversation. Policymakers and public health officials have rallied around dramatic claims fueled more by fear than by evidence. Yes, America faces a real crisis of chronic disease — including obesity, metabolic dysfunction and autoimmune disorders — which plausibly could be impacted by environmental toxins. Yes, many children face real mental health challenges that warrant increased attention and psychiatric support. But neither of these narratives survives scientific scrutiny when applied to the rise in autism diagnoses.

When public discourse starts from an alarming headline — “Autism rates have quadrupled” — even careful scientists can be pressured into chasing explanations for a biological phenomenon that doesn’t exist. The result is a misallocation of scientific effort and a blurring of the real signals of environmental harm. In many cases, the kid labeled “on the spectrum” is the same train‑obsessed third‑grader your grandfather knew, only now he’s been assigned a diagnosis. Let’s instead direct public health toward real, ongoing health crises and insist on psychiatric criteria that are consistent, unexaggerated and clinically meaningful.

A version of this article was published at the Washington Post on 2/10/2026.

eGenesis | Health Systems

Engineered Pig Kidneys Support First Reported Human Grafts

“eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced today clinical updates from an ongoing Expanded Access study of EGEN-2784, the Company’s genetically engineered porcine kidney for the treatment of kidney failure.

Since March 2024, five patients with kidney failure have received EGEN-2784 kidney transplants under Expanded Access in collaboration with the Mass General Brigham health system. Three of these patients have achieved sustained kidney function for more than eight months without the need for dialysis. One patient has surpassed nine months of dialysis independence, establishing a new global record for a genetically engineered porcine kidney transplant, and remains on study. Two of the five patients have successfully transitioned to human donor kidney transplants.

These two cases represent the first reported transitions from xenotransplantation to allotransplantation and provide important clinical evidence that transplantation with a genetically engineered porcine kidney can support a subsequent transplant with a human donor kidney. The experience of one of these patients, Tim Andrews, was published today in The Lancet. Andrews achieved approximately nine months of dialysis independence with an EGEN-2784 kidney before successfully receiving a human kidney 82 days following xenograft removal.”

From eGenesis.

UCL | Health Systems

First Real-Time AI Use in Brain Surgery Protects Patient’s Sight

“The first use of artificial intelligence to support a neurosurgeon in real time during live surgery has protected the sight of a man having a brain tumour removed, in a UCL-UCLH collaboration.

The operation was carried out at the National Hospital for Neurology and Neurosurgery (NHNN), UCLH, as part of a clinical trial using AI technology developed in-house at UCL and funded by the National Institute for Health and Care Research (NIHR).

Rhys Hibbert, aged 48 from Bedfordshire, a customer services manager and active community volunteer, is the first patient to have surgery in this way. Without surgery, Rhys’s tumour would have continued to threaten his sight and could ultimately have led to blindness. The operation successfully removed the tumour and protected his vision.

During his operation, the UCL-developed AI analysed the live surgical video feed in real time, rather than using pre-surgery scans, to help the surgical team make more precise decisions by highlighting critical structures at the base of the brain.

In this part of the brain, the pituitary gland (the size of a marble), blood vessels and nerves controlling vision are tightly packed together, and going a millimetre wrong can make a critical difference and lead to death, blindness or stroke. The AI supported the surgical team helping identify risky areas to avoid while removing as much tumour as safely possible. It also has the potential to track surgical instruments and instrument–tissue interactions, with the aim of supporting surgeons during complex procedures and providing feedback.”

From UCL.

ScienceDaily | Health & Medical Care

1-Month HEPA May Improve Mental Flexibility in Somerville 40+

“HEPA purifiers – HEPA stands for high efficiency particulate air – remove particulate matter from the air. Exposure to particulate matter has been connected to respiratory and cardiovascular illnesses as well as neurological diseases such as Alzheimer’s and Parkinson’s. Environmental health researchers increasingly recommend that people use HEPA air purifiers in their homes to lower their exposure to particulate matter, but few studies have examined whether using them boosts mental function.

We analyzed data from a study of 119 people ages 30 to 74 living in Somerville, Massachusetts. Somerville sits along Interstate 93 and Route 28, two major highways, resulting in relatively high levels of traffic-related air pollution. This makes it an especially good location for testing the health effects of air purifiers.

We randomly assigned participants to one of two groups. One used a HEPA air purifier for one month and then a sham air purifier – which looked and acted like the real thing but did not contain the air-cleaning filter – for one month, with a monthlong break in between. The second group used the real and sham purifiers in reverse order.

After each month, participants took a test that measured different aspects of their mental capacity. The test probed people’s visual memory and motor speed skills by measuring how quickly they could draw lines between sequential numbers, and it tested executive function and mental flexibility by asking them to draw lines between alternating sequential numbers and letters.

We found that participants 40 years and older – about 42% of our sample – on average completed the section testing for mental flexibility and executive function 12% faster after using the HEPA purifier than after using the sham purifier. That was true even when we accounted for factors like differences in the amount of time participants spent indoors, with either filter, as well as how stressful they found the test.”

From ScienceDaily.

World Health Organization | Water & Sanitation

Basic Water Services Reach More Health Care Facilities Worldwide

“A total of 84 countries and three SDG regions, representing 52% of the global population, had estimates for basic water services in health care facilities. Globally, 85% of health care facilities had basic water services, up from 76% in 2015. Coverage ranged from 57% in sub-Saharan Africa to 89% in Central and Southern Asia.”

From World Health Organization.